{"pmid":32470146,"title":"Elevated interleukin-6 is associated with severity of COVID-19: a meta-analysis.","text":["Elevated interleukin-6 is associated with severity of COVID-19: a meta-analysis.","Coronavirus disease 2019 (COVID-19) has spread rapidly around the world since its emergence in humans last December. Previous studies suggested that numerous markers of inflammation were elevated in patients in with severe disease relative to patients with milder conditions, and an elevated level of interleukin-6 (IL-6) was associated with a high case fatality of COVID-19 infection. This article is protected by copyright. All rights reserved.","J Med Virol","Zhu, Jieyun","Pang, Jielong","Ji, Pan","Zhong, Zhimei","Li, Hongyuan","Li, Bocheng","Zhang, Jianfeng","32470146"],"abstract":["Coronavirus disease 2019 (COVID-19) has spread rapidly around the world since its emergence in humans last December. Previous studies suggested that numerous markers of inflammation were elevated in patients in with severe disease relative to patients with milder conditions, and an elevated level of interleukin-6 (IL-6) was associated with a high case fatality of COVID-19 infection. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Zhu, Jieyun","Pang, Jielong","Ji, Pan","Zhong, Zhimei","Li, Hongyuan","Li, Bocheng","Zhang, Jianfeng"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32470146","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1002/jmv.26085","keywords":["2019 coronavirus disease","interleukin-6","meta-analysis","severe disease","critically ill"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1668420887313907712,"score":9.490897,"similar":[{"pmid":32343429,"title":"Elevated Interleukin-6 and Severe COVID-19: A Meta-Analysis.","text":["Elevated Interleukin-6 and Severe COVID-19: A Meta-Analysis.","Interleukin-6 is an important marker of inflammation. We performed a systematic review and meta-analysis to demonstrate the association of elevated IL-6 with severe Coronavirus disease-2019 (COVID-19). A total of 9 studies were included in the systematic review and meta-analysis. Patients with severe COVID-19 had a significantly higher serum IL-6 levels compared to non-severe patients (mean difference (MD): 38.6 pg/mL, 95% CI: 24.3 - 52.9 pg/mL, p <0.001, I2 = 98.5%). On meta-regression, increasing mean IL-6 level was associated with increased mortality in patients (Coefficient (Q): 0.01, 95% CI: 0.01-0.03, p = 0.03). Given the association of elevated IL-6 with severe COVID-19 and mortality, clinicians should use this as a potential marker to recognize severe disease. IL-6 should be incorporated in a scoring system along with other inflammatory markers to risk stratify the patients for early recognition of severe disease. Our study should encourage researchers to conduct trial evaluating Anti IL-6 antibodies such as Tocilizumab to assess the efficacy in patients with severe COVID-19. This article is protected by copyright. All rights reserved.","J Med Virol","Aziz, Muhammad","Fatima, Rawish","Assaly, Ragheb","32343429"],"abstract":["Interleukin-6 is an important marker of inflammation. We performed a systematic review and meta-analysis to demonstrate the association of elevated IL-6 with severe Coronavirus disease-2019 (COVID-19). A total of 9 studies were included in the systematic review and meta-analysis. Patients with severe COVID-19 had a significantly higher serum IL-6 levels compared to non-severe patients (mean difference (MD): 38.6 pg/mL, 95% CI: 24.3 - 52.9 pg/mL, p <0.001, I2 = 98.5%). On meta-regression, increasing mean IL-6 level was associated with increased mortality in patients (Coefficient (Q): 0.01, 95% CI: 0.01-0.03, p = 0.03). Given the association of elevated IL-6 with severe COVID-19 and mortality, clinicians should use this as a potential marker to recognize severe disease. IL-6 should be incorporated in a scoring system along with other inflammatory markers to risk stratify the patients for early recognition of severe disease. Our study should encourage researchers to conduct trial evaluating Anti IL-6 antibodies such as Tocilizumab to assess the efficacy in patients with severe COVID-19. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Aziz, Muhammad","Fatima, Rawish","Assaly, Ragheb"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32343429","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1002/jmv.25948","keywords":["immune responses","immune system < pathogenesis","pandemics < epidemiology","sars coronavirus < virus classification"],"e_drugs":["tocilizumab"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138495096193024,"score":216.54762},{"pmid":32484975,"title":"Myocardial injury characterized by elevated cardiac troponin and in-hospital mortality of COVID-19: an insight from a meta-analysis.","text":["Myocardial injury characterized by elevated cardiac troponin and in-hospital mortality of COVID-19: an insight from a meta-analysis.","Elevation of high-sensitivity cardiac troponin (hs-cTn) is a surrogate of myocardial injury, which appears to be a common complication of coronavirus disease 2019 (COVID-19). In this study, a meta-analysis was performed to clarify the association between myocardial injury assessed by hs-cTn levels and in-hospital mortality in patients with COVID-19. All existing studies on myocardial injury in patients with COVID-19 were retrieved from PubMed and EMBASE through April 13, 2020. In cases where overlap of the study population or enrollment period was found in articles published from the same hospitals, the article with the largest number of patients was only included in the analysis. The pooled odds ratio was calculated using inverse variance weighted random-effects models. Six observational studies which included a total of 1,231 patients met the search criteria. The percentage of patients with hs-cTn levels varied across the studies (13-41%). Elevated hs-cTn levels were significantly associated with an increase in in-hospital mortality (pooled odds ratio, 22.7; 95% confidence interval, 13.6-38.1; P<0.001) with a moderate heterogeneity (I(2) =28%), suggesting that elevated hs-cTn levels might be used as a reliable marker of disease severity early in the course of COVID-19. This article is protected by copyright. All rights reserved.","J Med Virol","Aikawa, Tadao","Takagi, Hisato","Ishikawa, Kiyotake","Kuno, Toshiki","32484975"],"abstract":["Elevation of high-sensitivity cardiac troponin (hs-cTn) is a surrogate of myocardial injury, which appears to be a common complication of coronavirus disease 2019 (COVID-19). In this study, a meta-analysis was performed to clarify the association between myocardial injury assessed by hs-cTn levels and in-hospital mortality in patients with COVID-19. All existing studies on myocardial injury in patients with COVID-19 were retrieved from PubMed and EMBASE through April 13, 2020. In cases where overlap of the study population or enrollment period was found in articles published from the same hospitals, the article with the largest number of patients was only included in the analysis. The pooled odds ratio was calculated using inverse variance weighted random-effects models. Six observational studies which included a total of 1,231 patients met the search criteria. The percentage of patients with hs-cTn levels varied across the studies (13-41%). Elevated hs-cTn levels were significantly associated with an increase in in-hospital mortality (pooled odds ratio, 22.7; 95% confidence interval, 13.6-38.1; P<0.001) with a moderate heterogeneity (I(2) =28%), suggesting that elevated hs-cTn levels might be used as a reliable marker of disease severity early in the course of COVID-19. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Aikawa, Tadao","Takagi, Hisato","Ishikawa, Kiyotake","Kuno, Toshiki"],"date":"2020-06-03T11:00:00Z","year":2020,"_id":"32484975","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1002/jmv.26108","keywords":["covid-19","coronavirus disease 2019","high-sensitivity cardiac troponin","in-hospital mortality","meta-analysis","myocardial injury"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1668532114837995521,"score":155.95502},{"pmid":32425269,"pmcid":"PMC7233239","title":"Elevated levels of interleukin-6 and CRP predict the need for mechanical ventilation in COVID-19.","text":["Elevated levels of interleukin-6 and CRP predict the need for mechanical ventilation in COVID-19.","Background: COVID-19 can manifest as a viral induced hyperinflammation with multi-organ involvement. Such patients often experience rapid deterioration and need for mechanical ventilation. Currently, no prospectively validated biomarker of impending respiratory failure is available. Objective: We aimed to identify and prospectively validate biomarkers that allow the identification of patients in need of impending mechanical ventilation. Methods: Patients with COVID-19 hospitalized from February 29(th) to April 09(th), 2020 were analyzed for baseline clinical and laboratory findings at admission and during the disease. Data from 89 evaluable patients were available for the purpose of analysis comprising an initial evaluation cohort (n=40) followed by a temporally separated validation cohort (n=49). Results: We identified markers of inflammation, LDH and creatinine as most predictive variables of respiratory failure in the evaluation cohort. Maximal interleukin-6 (IL-6) levels before intubation showed the strongest association with the need of mechanical ventilation followed by maximal CRP. Respective AUC values for IL-6 and CRP in the evaluation cohort were 0.97 and 0.86 and similar in the validation cohort 0.90 and 0.83. The calculated optimal cutoff values in the course of disease from the evaluation cohort (IL-6> 80 pg/ml and CRP> 97 mg/l) both correctly classified 80% of patients in the validation cohort regarding their risk of respiratory failure. Conclusion: Maximal levels of IL-6 followed by CRP were highly predictive of the need for mechanical ventilation. This suggests the possibility of using IL-6 or CRP levels to guide escalation of treatment in patients with COVID-19 related hyperinflammatory syndrome.","J Allergy Clin Immunol","Herold, Tobias","Jurinovic, Vindi","Arnreich, Chiara","Lipworth, Brian J","Hellmuth, Johannes C","von Bergwelt-Baildon, Michael","Klein, Matthias","Weinberger, Tobias","32425269"],"abstract":["Background: COVID-19 can manifest as a viral induced hyperinflammation with multi-organ involvement. Such patients often experience rapid deterioration and need for mechanical ventilation. Currently, no prospectively validated biomarker of impending respiratory failure is available. Objective: We aimed to identify and prospectively validate biomarkers that allow the identification of patients in need of impending mechanical ventilation. Methods: Patients with COVID-19 hospitalized from February 29(th) to April 09(th), 2020 were analyzed for baseline clinical and laboratory findings at admission and during the disease. Data from 89 evaluable patients were available for the purpose of analysis comprising an initial evaluation cohort (n=40) followed by a temporally separated validation cohort (n=49). Results: We identified markers of inflammation, LDH and creatinine as most predictive variables of respiratory failure in the evaluation cohort. Maximal interleukin-6 (IL-6) levels before intubation showed the strongest association with the need of mechanical ventilation followed by maximal CRP. Respective AUC values for IL-6 and CRP in the evaluation cohort were 0.97 and 0.86 and similar in the validation cohort 0.90 and 0.83. The calculated optimal cutoff values in the course of disease from the evaluation cohort (IL-6> 80 pg/ml and CRP> 97 mg/l) both correctly classified 80% of patients in the validation cohort regarding their risk of respiratory failure. Conclusion: Maximal levels of IL-6 followed by CRP were highly predictive of the need for mechanical ventilation. This suggests the possibility of using IL-6 or CRP levels to guide escalation of treatment in patients with COVID-19 related hyperinflammatory syndrome."],"journal":"J Allergy Clin Immunol","authors":["Herold, Tobias","Jurinovic, Vindi","Arnreich, Chiara","Lipworth, Brian J","Hellmuth, Johannes C","von Bergwelt-Baildon, Michael","Klein, Matthias","Weinberger, Tobias"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425269","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.jaci.2020.05.008","keywords":["covid-19","crp","il-6","interleukin-6","hyperinflammation","mechanical ventilation","prediction","respiratory failure"],"e_drugs":["Creatinine"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1667252837986336769,"score":151.49763},{"pmid":32428990,"title":"The role of interleukin-6 in monitoring severe case of coronavirus disease 2019.","text":["The role of interleukin-6 in monitoring severe case of coronavirus disease 2019.","Progression to severe disease is a difficult problem in treating coronavirus disease 2019 (COVID-19). The purpose of this study is to explore changes in markers of severe disease in COVID-19 patients. 69 severe COVID-19 patients were included. Patients with severe disease showed significant lymphocytopenia. Elevated level of lactate dehydrogenase (LDH), C-reactive protein (CRP), ferritin and D-dimer was found in most severe cases. Baseline interleukin-6 (IL-6) was found to be associated with COVID-19 severity. Indeed, the significant increase of baseline IL-6 was positively correlated to the maximal body temperature during hospitalization and to the increased baseline of CRP, LDH, ferritin and D-dimer. High baseline IL-6 was also associated with more progressed chest computed tomography (CT) findings. Significant decrease in IL-6 and improved CT assessment was found in patients during recovery, while IL-6 was further increased in exacerbated patients. Collectively, our results suggest that the dynamic change in IL-6 can be used as a marker for disease monitoring in patients with severe COVID-19.","EMBO Mol Med","Liu, Tao","Zhang, Jieying","Yang, Yuhui","Ma, Hong","Li, Zhenyu","Zhang, Jiaoyue","Cheng, Ji","Zhang, Xiaoyun","Zhao, Yanxia","Xia, Zihan","Zhang, Liling","Wu, Gang","Yi, Jianhua","32428990"],"abstract":["Progression to severe disease is a difficult problem in treating coronavirus disease 2019 (COVID-19). The purpose of this study is to explore changes in markers of severe disease in COVID-19 patients. 69 severe COVID-19 patients were included. Patients with severe disease showed significant lymphocytopenia. Elevated level of lactate dehydrogenase (LDH), C-reactive protein (CRP), ferritin and D-dimer was found in most severe cases. Baseline interleukin-6 (IL-6) was found to be associated with COVID-19 severity. Indeed, the significant increase of baseline IL-6 was positively correlated to the maximal body temperature during hospitalization and to the increased baseline of CRP, LDH, ferritin and D-dimer. High baseline IL-6 was also associated with more progressed chest computed tomography (CT) findings. Significant decrease in IL-6 and improved CT assessment was found in patients during recovery, while IL-6 was further increased in exacerbated patients. Collectively, our results suggest that the dynamic change in IL-6 can be used as a marker for disease monitoring in patients with severe COVID-19."],"journal":"EMBO Mol Med","authors":["Liu, Tao","Zhang, Jieying","Yang, Yuhui","Ma, Hong","Li, Zhenyu","Zhang, Jiaoyue","Cheng, Ji","Zhang, Xiaoyun","Zhao, Yanxia","Xia, Zihan","Zhang, Liling","Wu, Gang","Yi, Jianhua"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32428990","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.15252/emmm.202012421","keywords":["biomarker","coronavirus disease 2019: interleukin-6","cytokine storm","disease monitoring"],"topics":["Diagnosis"],"weight":1,"_version_":1667352728856166401,"score":132.15363},{"pmid":32441789,"title":"Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis.","text":["Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis.","Mortality rates of coronavirus disease 2019 (COVID-19) continue to rise across the world. Information regarding the predictors of mortality in COVID-19 patients remains scarce. Herein, we performed a systematic review of published articles, from January 1 to April 24, 2020, to evaluate the risk factors associated with mortality in COVID-19. Two investigators independently searched the articles and collected the data, in accordance with PRISMA guidelines. We looked for associations between mortality and patient characteristics, comorbidities, and laboratory abnormalities. A total of 14 studies documenting the outcomes of 4659 patients were included. The presence of comorbidities such as hypertension (OR 2.5; 95% CI 2.1-3.1; P<0.00001), coronary heart disease (OR 3.8; 95% CI 2.1-6.9; P<0.00001) and diabetes (OR 2.0; 95% CI 1.7-2.3; P<0.00001) were associated with significantly higher risk of death amongst COVID-19 patients. Those who died, compared to those who survived, differed on multiple biomarker levels on admission including elevated levels of cardiac troponin (+44.2 ng/L, 95% CI 19.0-69.4; P=0.0006); C-reactive protein (+66.3 microg/mL, 95% CI 46.7-85.9; P<0.00001); interleukin-6 (+4.6 ng/mL, 95% CI 3.6-5.6; P<0.00001); D-dimer (+4.6 microg/mL, 95% CI 2.8-6.4; P<0.00001); creatinine (+15.3 micromol/L, 95% CI 6.2-24.3; P=0.001) and alanine transaminase (+5.7 U/L, 95% CI 2.6-8.8; P=0.0003); as well as decreased levels of albumin (-3.7 g/L, 95% CI -5.3 to -2.1; P<0.00001). Individuals with underlying cardiometabolic disease and that present with evidence for acute inflammation and end-organ damage are at higher risk of mortality due to COVID-19 infection and should be managed with greater intensity. This article is protected by copyright. All rights reserved.","J Med Virol","Tian, Wenjie","Jiang, Wanlin","Yao, Jie","Nicholson, Christopher J","Li, Rebecca H","Sigurslid, Haakon H","Wooster, Luke","Rotter, Jerome I","Guo, Xiuqing","Malhotra, Rajeev","32441789"],"abstract":["Mortality rates of coronavirus disease 2019 (COVID-19) continue to rise across the world. Information regarding the predictors of mortality in COVID-19 patients remains scarce. Herein, we performed a systematic review of published articles, from January 1 to April 24, 2020, to evaluate the risk factors associated with mortality in COVID-19. Two investigators independently searched the articles and collected the data, in accordance with PRISMA guidelines. We looked for associations between mortality and patient characteristics, comorbidities, and laboratory abnormalities. A total of 14 studies documenting the outcomes of 4659 patients were included. The presence of comorbidities such as hypertension (OR 2.5; 95% CI 2.1-3.1; P<0.00001), coronary heart disease (OR 3.8; 95% CI 2.1-6.9; P<0.00001) and diabetes (OR 2.0; 95% CI 1.7-2.3; P<0.00001) were associated with significantly higher risk of death amongst COVID-19 patients. Those who died, compared to those who survived, differed on multiple biomarker levels on admission including elevated levels of cardiac troponin (+44.2 ng/L, 95% CI 19.0-69.4; P=0.0006); C-reactive protein (+66.3 microg/mL, 95% CI 46.7-85.9; P<0.00001); interleukin-6 (+4.6 ng/mL, 95% CI 3.6-5.6; P<0.00001); D-dimer (+4.6 microg/mL, 95% CI 2.8-6.4; P<0.00001); creatinine (+15.3 micromol/L, 95% CI 6.2-24.3; P=0.001) and alanine transaminase (+5.7 U/L, 95% CI 2.6-8.8; P=0.0003); as well as decreased levels of albumin (-3.7 g/L, 95% CI -5.3 to -2.1; P<0.00001). Individuals with underlying cardiometabolic disease and that present with evidence for acute inflammation and end-organ damage are at higher risk of mortality due to COVID-19 infection and should be managed with greater intensity. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Tian, Wenjie","Jiang, Wanlin","Yao, Jie","Nicholson, Christopher J","Li, Rebecca H","Sigurslid, Haakon H","Wooster, Luke","Rotter, Jerome I","Guo, Xiuqing","Malhotra, Rajeev"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32441789","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1002/jmv.26050","keywords":["covid-19","cardiovascular disease","diabetes","meta-analysis"],"e_drugs":["Creatinine"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1667523504784801793,"score":129.05193}]}